The United States-Mexico-Canada Agreement keeps biologic drug prices high but could potentially spur new research opportunities, a pharmaceutical expert told Healio Family Medicine.
The agreement between the three countries announced on Nov. 30, but still subject to approval by Congress and legislatures in Canada and Mexico, will significantly change how the U.S. does business with some of its closest geographic neighbors, members of President Donald J. Trump’s administration said.
“This paradigm-shifting model ... will consist of a host of ambitious provisions on digital trade;
Uncategorized